Efficacy of Eplerenone monotherapy and Valsartan monotherapy on patients of Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension.

Efficacy of Eplerenone monotherapy and Valsartan monotherapy on patients of Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension. - A pilot study to compare efficacy of Eplerenone monotherapy with Valsartan monotherapy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002925

Enrollment

Registered

2009-12-28

Start date

2009-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subclinical Cushing&#39

Interventions

50mg of Eplerenone monotherapy once daily for 6 weeks on subclinical Cushing&#39

s syndrome 80mg of Valsartan monotherapy once daily for 6 weeks on subclinical Cushing&#39

s syndrome 50mg of Eplerenone monotherapy once daily for 6 weeks on non-functioning adrenocortical adenoma 80mg of Valsartan monotherapy once daily for 6 weeks on non-functioning adrenocortical adenom

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (a) Patients with hypertension(>=130/80mmHg) (b)Patients are outpatients or inpatients

Exclusion criteria

Exclusion criteria: (a) Patients with a history of severe cardiovascular or cerebrovascular disease or renal failure. (b) Patients with aldosterone producing adenoma, Cushing's syndrome and malignant tumor. (c) Patients who have taken ARB, ACEI, aldosterone antagonist or diuretics therapy. (d) Patients have contraindication of Eplerenone and Valsartan. (e) Patients with severe liver damage. (f) Patients are pregnant or patients breast-feeding, potentially pregnant. (g) Patients who are diagnosed to be ineligible by the investigator

Design outcomes

Primary

Measure	Time frame
Lowering rate of urinary 8-OHdG and urinary 8-Isoprostane from baseline after 6 weeks.	—

Secondary

Measure	Time frame
Lowering rate of blood pressure and CRP from baseline after 6 weeks.	—

Countries

Japan

Contacts

Public ContactTsuguka Shiwa

Hiroshima University Hospital Department of Endocrinology and Diabetes mellitus

tsuguka@hiroshima-u.ac.jp082-257-5196

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Efficacy of Eplerenone monotherapy and Valsartan monotherapy on patients of Subclinical Cushing&#39;s syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension.